/COR
Cencora, Inc.
COR • NYSECOR • NYSE • Healthcare
$368.19-0.87%-3.25
$368.19-0.87%(-3.25)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
75Bullish
Risk
94Low Risk
Momentum
78Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
3.2%▲0.2pp
Revenue after COGS
Operating
1.1%▲0.1pp
After operating expenses
Net
0.5%▼0.0pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
39.0
Price vs earnings
EV/EBITDA
17.9
Enterprise value
FCF Yield
5.3%
Cash generation
Earnings Yield
2.6%
Inverse of P/E
Capital Efficiency
38
GoAI Quality ScoreExcellent
ROEReturn on Equity
103.1%Strong
ROAReturn on Assets
2.0%Fair
ROICReturn on Invested Capital
13.2%Strong
Financial Health
Current RatioWeak
0.90
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
1.70x
Debt repayment capacity (<3x)
Income QualityStrong
2.47
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B |
| Gross Profit | $10.14B | $8.70B | $7.76B | $7.60B | $6.27B |
| Gross Margin | 3.2% | 3.0% | 3.0% | 3.2% | 2.9% |
| Operating Income | $3.65B | $3.04B | $2.45B | $2.75B | $2.68B |
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B |
| Net Margin | 0.5% | 0.5% | 0.7% | 0.7% | 0.7% |
| EPS | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 |
Average Price Target
$410.50▲ 11.5% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Cencora, Inc., the average price target is $410.50, with a high forecast of $440.00 and a low forecast of $340.00. The average price target represents a 11.5% increase from the current price of $368.19.
Highest
$440.00
Average
$410.50
Lowest
$340.00
Rating Distribution
Strong Buy
0
0%
Buy
33
72%
Hold
12
26%
Sell
1
2%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Overweight
2026-02-13Wells Fargo● Maintain
Overweight
2026-02-10JP Morgan● Maintain
Overweight
2026-02-10Evercore ISI Group● Maintain
Outperform
2026-02-05Morgan Stanley▲ Upgrade
Equal Weight→Overweight
2026-01-29Jefferies▲ Upgrade
Hold→Buy
2026-01-22B of A Securities● Maintain
Neutral
2026-01-05Wells Fargo● Maintain
Overweight
2025-11-11JP Morgan● Maintain
Overweight
2025-11-11TD Cowen● Maintain
Buy
2025-11-10Earnings History & Surprises
BEAT RATE
88%
Last 16 quarters
AVG SURPRISE
+1.2%
EPS vs Estimate
BEATS / MISSES
14/1
1 met exactly
LATEST EPS
$4.08
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+0.7%
$4.08 vs $4.05
Q4 '25
+1.3%
$3.84 vs $3.79
Q3 '25
+3.9%
$4.00 vs $3.85
Q2 '25
+7.5%
$4.42 vs $4.11
Q1 '25
+6.6%
$3.73 vs $3.50
Q4 '24
+3.4%
$3.34 vs $3.23
Q1 '24
No data
Q4 '23
-38.4%
$1.72 vs $2.79
Q3 '23
+3.5%
$2.92 vs $2.82
Q2 '23
+6.4%
$3.50 vs $3.29
Q1 '23
+2.7%
$2.71 vs $2.64
Q4 '22
+0.8%
$2.60 vs $2.58
No investor questions available.
Latest News
No news available